Oxolamine Citrate

Oxolamine Citrate (CAS No.: 1949-20-8) is a synthetic small molecule and pharmaceutically relevant citrate salt that is primarily classified in research settings as an antitussive associated with respiratory pharmacology and inflammation focused discovery programs, with documented biochemical activity as an inhibitor of CYP2B family enzymes including CYP2B1 and CYP2B2 and with preclinical evidence of anti inflammatory effects in respiratory tissues in animal models such as guinea pig systems, supporting its use as a tool compound for investigating xenobiotic metabolism respiratory tract inflammatory biology and exposure interaction liabilities in nonclinical workflows; within biomedical research and early drug discovery it is commonly positioned for mechanism oriented studies of enzyme modulation and pharmacokinetic interaction risk, including observations that it can increase systemic exposure and prolong terminal half life of co administered probe compounds in preclinical contexts, while quantitative potency parameters such as IC50 or EC50 are not consistently disclosed in the provided sources and are therefore best treated as context dependent and to be empirically resolved, often in screening cascades spanning nanomolar to micromolar concentration windows where appropriate assay systems are available; typical applications include cell based metabolism or inflammation related assays, exploratory pathway level profiling relevant to cytochrome mediated biotransformation networks, and in vivo pharmacology models of respiratory biology, with the concentrations or doses used in experiments typically depending on specific experimental designs and research objectives.